Literature DB >> 23507827

The peritoneal-renal syndrome.

Sharon J Nessim1, Joanne M Bargman.   

Abstract

In patients on peritoneal dialysis (PD), a strong inter-relationship exists between the peritoneal membrane and the kidney. This Perspectives article will focus on the mechanisms by which alterations in peritoneal membrane function may influence residual renal function and vice versa. In addition, it will discuss how exposure to PD solutions and inhibitors of the renin-angiotensin-aldosterone system can simultaneously affect both the peritoneal membrane and the kidney. Similar to the cardiorenal syndrome, where changes in one organ system result in changes in the other, we propose the existence of a 'peritoneal-renal syndrome', with this novel term encompassing the complex interaction between the peritoneal membrane and the kidneys among patients on PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23507827     DOI: 10.1038/nrneph.2013.43

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  63 in total

1.  Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function.

Authors:  Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil C Boudville; Kathryn J Wiggins; Kym M Bannister; David W Johnson
Journal:  Nephrol Dial Transplant       Date:  2011-06-01       Impact factor: 5.992

2.  Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect.

Authors:  M Girndt; M Sester; U Sester; H Kaul; H Köhler
Journal:  Kidney Int       Date:  2001-04       Impact factor: 10.612

3.  Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription.

Authors:  Simon J Davies; Edwina A Brown; Niels E Frandsen; Anabela S Rodrigues; Ana Rodriguez-Carmona; Andreas Vychytil; Evelyne Macnamara; Agneta Ekstrand; Anders Tranaeus; Jose C Divino Filho
Journal:  Kidney Int       Date:  2005-04       Impact factor: 10.612

4.  Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK.

Authors:  Kei Kiribayashi; Takao Masaki; Takayuki Naito; Takahiko Ogawa; Takafumi Ito; Noriaki Yorioka; Nobuoki Kohno
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

5.  Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange.

Authors:  Simon J Davies; Elvia Garcia Lopez; Graham Woodrow; Kieron Donovan; Jorg Plum; Paul Williams; Ann Catherine Johansson; Hans-Peter Bosselmann; Olof Heimburger; Ole Simonsen; Andrew Davenport; Bengt Lindholm; Anders Tranaeus; Jose C Divino Filho
Journal:  Nephrol Dial Transplant       Date:  2008-05-02       Impact factor: 5.992

6.  Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.

Authors:  S L S Fan; T Pile; S Punzalan; M J Raftery; M M Yaqoob
Journal:  Kidney Int       Date:  2007-10-03       Impact factor: 10.612

7.  Cell function and viability in glucose polymer peritoneal dialysis fluids.

Authors:  T Liberek; N Topley; C D Mistry; G A Coles; T Morgan; R A Quirk; J D Williams
Journal:  Perit Dial Int       Date:  1993       Impact factor: 1.756

8.  Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients.

Authors:  Kook-Hwan Oh; Ju-Young Moon; Jieun Oh; Seong Gyun Kim; Young-Hwan Hwang; Suhnggwon Kim; Jung Sang Lee; Curie Ahn
Journal:  Nephrol Dial Transplant       Date:  2008-01-04       Impact factor: 5.992

9.  Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.

Authors:  Hiromichi Suzuki; Yoshihiko Kanno; Soichi Sugahara; Hirokazu Okada; Hidetomo Nakamoto
Journal:  Am J Kidney Dis       Date:  2004-06       Impact factor: 8.860

10.  Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients.

Authors:  Markus Rumpsfeld; Stephen P McDonald; David M Purdie; John Collins; David W Johnson
Journal:  Am J Kidney Dis       Date:  2004-03       Impact factor: 8.860

View more
  5 in total

Review 1.  Volume control in treatment-resistant congestive heart failure: role for peritoneal dialysis.

Authors:  K E Broekman; S J Sinkeler; F Waanders; G L Bartels; G Navis; W M T Janssen
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

2.  Valsartan ameliorates high glucose-induced peritoneal fibrosis by blocking mTORC1 signaling.

Authors:  Jing Liu; Yuan Feng; Cheng Sun; Wei Zhu; Qing-Yan Zhang; Bo Jin; Qiu-Yuan Shao; Yang-Yang Xia; Peng-Fei Xu; Miao Zhang; Chun-Ming Jiang
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-14

3.  [Effect of dietary sodium intake on residual renal function in patients undergoing peritoneal dialysis: a prospective study of 33 cases].

Authors:  Jianxia Hu; Liping Hu; Nirong Gong; Lei Zhang; Jianwei Tian; Jianping Jiang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-06-30

4.  Effectiveness of Renin-Angiotensin-Aldosterone System Blockade on Residual Kidney Function and Peritoneal Membrane Function in Peritoneal Dialysis Patients: A Network Meta-Analysis.

Authors:  Sirayut Phatthanasobhon; Surapon Nochaiwong; Kednapa Thavorn; Kajohnsak Noppakun; Setthapon Panyathong; Yuttitham Suteeka; Brian Hutton; Manish M Sood; Greg A Knoll; Chidchanok Ruengorn
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

5.  Arctigenin protects mice from thioglycollate-induced acute peritonitis.

Authors:  Jingyi Zhao; Ying Chen; Lijun Dong; Xin Li; Ruijie Dong; Dongmei Zhou; Chengzhi Wang; Xiangdong Guo; Jieyou Zhang; Zhenyi Xue; Qing Xi; Lijuan Zhang; Guangze Yang; Yan Li; Rongxin Zhang
Journal:  Pharmacol Res Perspect       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.